title: The effects of aspirin on platelet function and lysophosphatidic acids depend on plasma concentrations of EPA and DHA.
abstract: Aspirin's prevention of cardiovascular disease (CVD) events in individuals with type 2 diabetes mellitus is controversial. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and aspirin all affect the cyclooxygenase enzyme. The relationship between plasma EPA and DHA and aspirin's effects has not been determined. Thirty adults with type 2 diabetes mellitus ingested aspirin (81 mg/day) for 7 days, then EPA+DHA (2.6g/day) for 28 days, then both for another 7 days. Lysophosphatidic acid (LPA) species and more classic platelet function outcomes were determined. Plasma concentrations of total EPA+DHA were associated with 7-day aspirin reduction effects on these outcomes in a "V"-shaped manner for all 11 LPA species and ADP-induced platelet aggregation. This EPA+DHA concentration was quite consistent for each of the LPA species and ADP. These results support aspirin effects on lysolipid metabolism and platelet aggregation depending on plasma EPA+DHA concentrations in individuals with a disturbed lipid milieu.
authors.affiliation: Department of Public Health Sciences, University of Rochester, School of Medicine and Dentistry, 265 Crittenden Boulevard, Box CU 420644, Rochester, NY 14642, USA. Electronic address: robert_block@urmc.rochester.edu.
authors.forename: Robert C
authors.initials: RC
authors.lastname: Block
authors.affiliation: Department of Public Health Sciences, University of Rochester, School of Medicine and Dentistry, 265 Crittenden Boulevard, Box CU 420644, Rochester, NY 14642, USA.
authors.forename: Amir
authors.initials: A
authors.lastname: Abdolahi
authors.affiliation: Department of Biostatistics and Computational Biology, University of Rochester, School of Medicine and Dentistry, 265 Crittenden Boulevard, Box CU 420644, Rochester, NY 14642 USA.
authors.forename: Xin
authors.initials: X
authors.lastname: Tu
authors.affiliation: Pulmonary and Critical Care Division, Department of Medicine, University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA.
authors.forename: Steve N
authors.initials: SN
authors.lastname: Georas
authors.affiliation: Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.
authors.forename: J Thomas
authors.initials: JT
authors.lastname: Brenna
authors.affiliation: Department of Environmental Medicine, University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA.
authors.forename: Richard P
authors.initials: RP
authors.lastname: Phipps
authors.affiliation: Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Lawrence
authors.affiliation: Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA.
authors.forename: Shaker A
authors.initials: SA
authors.lastname: Mousa
mesh_terms: D000328:Adult; D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism; D004281:Docosahexaenoic Acids / Q000097:blood* / Q000494:pharmacology; D015118:Eicosapentaenoic Acid / Q000097:blood* / Q000494:pharmacology; D005231:Fatty Acids, Unsaturated / Q000097:blood / Q000494:pharmacology; D005260:Female; D006801:Humans; D008246:Lysophospholipids / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*
chemical_list: D005231:Fatty Acids, Unsaturated; D008246:Lysophospholipids; D010975:Platelet Aggregation Inhibitors; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid; C032881:lysophosphatidic acid; D001241:Aspirin
keywords: Aspirin; Docosahexaenoic acid; Eicosapentaenoic acid; Lysophosphatidic acid; Lysophosphatidylcholine; Platelet function